Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data.

Zardavas D, Te Marvelde L, Milne RL, Fumagalli D, Fountzilas G, Kotoula V, Razis E, Papaxoinis G, Joensuu H, Moynahan ME, Hennessy BT, Bieche I, Saal LH, Stal O, Iacopetta B, Jensen JD, O'Toole S, Lopez-Knowles E, Barbaraeschi M, Noguchi S, Azim HA Jr, Lerma E, Bachelot T, Wang Q, Perez-Tenorio G, Can de Velde CJH, Rea DW, Sabine V, Bartlett JMS, Sotiriou C, Michiels S, Loi S.

J Clin Oncol. 2018 Apr 1;36(10):981-990. doi: 10.1200/JCO.2017.74.8301. Epub 2018 Feb 22.

2.

ATM loss leads to synthetic lethality in BRCA1 BRCT mutant mice associated with exacerbated defects in homology-directed repair.

Chen CC, Kass EM, Yen WF, Ludwig T, Moynahan ME, Chaudhuri J, Jasin M.

Proc Natl Acad Sci U S A. 2017 Jul 18;114(29):7665-7670. doi: 10.1073/pnas.1706392114. Epub 2017 Jun 28.

3.

Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2- advanced breast cancer: results from BOLERO-2.

Moynahan ME, Chen D, He W, Sung P, Samoila A, You D, Bhatt T, Patel P, Ringeisen F, Hortobagyi GN, Baselga J, Chandarlapaty S.

Br J Cancer. 2017 Mar 14;116(6):726-730. doi: 10.1038/bjc.2017.25. Epub 2017 Feb 9.

4.

Robust homology-directed repair within mouse mammary tissue is not specifically affected by Brca2 mutation.

Kass EM, Lim PX, Helgadottir HR, Moynahan ME, Jasin M.

Nat Commun. 2016 Oct 25;7:13241. doi: 10.1038/ncomms13241.

5.

Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial.

Chandarlapaty S, Chen D, He W, Sung P, Samoila A, You D, Bhatt T, Patel P, Voi M, Gnant M, Hortobagyi G, Baselga J, Moynahan ME.

JAMA Oncol. 2016 Oct 1;2(10):1310-1315. doi: 10.1001/jamaoncol.2016.1279.

6.

PARP Inhibitors in Clinical Use Induce Genomic Instability in Normal Human Cells.

Ito S, Murphy CG, Doubrovina E, Jasin M, Moynahan ME.

PLoS One. 2016 Jul 18;11(7):e0159341. doi: 10.1371/journal.pone.0159341. eCollection 2016.

7.

When Genome Maintenance Goes Badly Awry.

Kass EM, Moynahan ME, Jasin M.

Mol Cell. 2016 Jun 2;62(5):777-87. doi: 10.1016/j.molcel.2016.05.021. Review.

8.

Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance).

Dickler MN, Barry WT, Cirrincione CT, Ellis MJ, Moynahan ME, Innocenti F, Hurria A, Rugo HS, Lake DE, Hahn O, Schneider BP, Tripathy D, Carey LA, Winer EP, Hudis CA.

J Clin Oncol. 2016 Aug 1;34(22):2602-9. doi: 10.1200/JCO.2015.66.1595. Epub 2016 May 2.

9.

Reverse-Contrast Imaging and Targeted Radiation Therapy of Advanced Pancreatic Cancer Models.

Thorek DL, Kramer RM, Chen Q, Jeong J, Lupu ME, Lee AM, Moynahan ME, Lowery M, Ulmert D, Zanzonico P, Deasy JO, Humm JL, Russell J.

Int J Radiat Oncol Biol Phys. 2015 Oct 1;93(2):444-53. doi: 10.1016/j.ijrobp.2015.06.001. Epub 2015 Jun 9.

10.

Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.

Dang C, Iyengar N, Datko F, D'Andrea G, Theodoulou M, Dickler M, Goldfarb S, Lake D, Fasano J, Fornier M, Gilewski T, Modi S, Gajria D, Moynahan ME, Hamilton N, Patil S, Jochelson M, Norton L, Baselga J, Hudis C.

J Clin Oncol. 2015 Feb 10;33(5):442-7. doi: 10.1200/JCO.2014.57.1745. Epub 2014 Dec 29. Erratum in: J Clin Oncol. 2019 Feb 1;37(4):354.

11.

A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer.

Jhaveri K, Chandarlapaty S, Lake D, Gilewski T, Robson M, Goldfarb S, Drullinsky P, Sugarman S, Wasserheit-Leiblich C, Fasano J, Moynahan ME, D'Andrea G, Lim K, Reddington L, Haque S, Patil S, Bauman L, Vukovic V, El-Hariry I, Hudis C, Modi S.

Clin Breast Cancer. 2014 Jun;14(3):154-60. doi: 10.1016/j.clbc.2013.12.012. Epub 2013 Dec 28.

PMID:
24512858
12.

Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.

Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, Blackwell K, Rugo H, Nabell L, Forero A, Stearns V, Doane AS, Danso M, Moynahan ME, Momen LF, Gonzalez JM, Akhtar A, Giri DD, Patil S, Feigin KN, Hudis CA, Traina TA; Translational Breast Cancer Research Consortium (TBCRC 011).

Clin Cancer Res. 2013 Oct 1;19(19):5505-12. doi: 10.1158/1078-0432.CCR-12-3327. Epub 2013 Aug 21.

13.

Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast cancer.

Seidman AD, Conlin AK, Bach A, Moynahan ME, Lake D, Forero A, Wright GS, Hackney MH, Clawson A, Norton L, Hudis CA.

Clin Breast Cancer. 2013 Aug;13(4):239-246.e1. doi: 10.1016/j.clbc.2013.02.008.

PMID:
23829890
14.

Double-strand break repair by homologous recombination in primary mouse somatic cells requires BRCA1 but not the ATM kinase.

Kass EM, Helgadottir HR, Chen CC, Barbera M, Wang R, Westermark UK, Ludwig T, Moynahan ME, Jasin M.

Proc Natl Acad Sci U S A. 2013 Apr 2;110(14):5564-9. doi: 10.1073/pnas.1216824110. Epub 2013 Mar 18.

15.

Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition.

Cavallo F, Graziani G, Antinozzi C, Feldman DR, Houldsworth J, Bosl GJ, Chaganti RS, Moynahan ME, Jasin M, Barchi M.

PLoS One. 2012;7(12):e51563. doi: 10.1371/journal.pone.0051563. Epub 2012 Dec 12.

16.

PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression.

Kalinsky K, Heguy A, Bhanot UK, Patil S, Moynahan ME.

Breast Cancer Res Treat. 2011 Sep;129(2):635-43. doi: 10.1007/s10549-011-1601-4. Epub 2011 May 27.

PMID:
21617917
17.

HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.

Modi S, Stopeck A, Linden H, Solit D, Chandarlapaty S, Rosen N, D'Andrea G, Dickler M, Moynahan ME, Sugarman S, Ma W, Patil S, Norton L, Hannah AL, Hudis C.

Clin Cancer Res. 2011 Aug 1;17(15):5132-9. doi: 10.1158/1078-0432.CCR-11-0072. Epub 2011 May 10.

18.

Breast cancer methylomes establish an epigenomic foundation for metastasis.

Fang F, Turcan S, Rimner A, Kaufman A, Giri D, Morris LG, Shen R, Seshan V, Mo Q, Heguy A, Baylin SB, Ahuja N, Viale A, Massague J, Norton L, Vahdat LT, Moynahan ME, Chan TA.

Sci Transl Med. 2011 Mar 23;3(75):75ra25. doi: 10.1126/scitranslmed.3001875.

19.

Homology-directed Fanconi anemia pathway cross-link repair is dependent on DNA replication.

Nakanishi K, Cavallo F, Perrouault L, Giovannangeli C, Moynahan ME, Barchi M, Brunet E, Jasin M.

Nat Struct Mol Biol. 2011 Apr;18(4):500-3. doi: 10.1038/nsmb.2029. Epub 2011 Mar 20.

20.

A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer.

McArthur HL, Rugo H, Nulsen B, Hawks L, Grothusen J, Melisko M, Moasser M, Paulson M, Traina T, Patil S, Zhou Q, Steingart R, Dang C, Morrow M, Cordeiro P, Fornier M, Park J, Seidman A, Lake D, Gilewski T, Theodoulou M, Modi S, D'Andrea G, Sklarin N, Robson M, Moynahan ME, Sugarman S, Sealey JE, Laragh JH, Merali C, Norton L, Hudis CA, Dickler MN.

Clin Cancer Res. 2011 May 15;17(10):3398-407. doi: 10.1158/1078-0432.CCR-10-1969. Epub 2011 Feb 24.

21.

Loss of 53BP1 is a gain for BRCA1 mutant cells.

Kass EM, Moynahan ME, Jasin M.

Cancer Cell. 2010 May 18;17(5):423-5. doi: 10.1016/j.ccr.2010.04.021.

22.

Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis.

Moynahan ME, Jasin M.

Nat Rev Mol Cell Biol. 2010 Mar;11(3):196-207. doi: 10.1038/nrm2851. Review.

23.

BRCA gene structure and function in tumor suppression: a repair-centric perspective.

Murphy CG, Moynahan ME.

Cancer J. 2010 Jan-Feb;16(1):39-47. doi: 10.1097/PPO.0b013e3181cf0204. Review.

PMID:
20164689
24.

PIK3CA mutation associates with improved outcome in breast cancer.

Kalinsky K, Jacks LM, Heguy A, Patil S, Drobnjak M, Bhanot UK, Hedvat CV, Traina TA, Solit D, Gerald W, Moynahan ME.

Clin Cancer Res. 2009 Aug 15;15(16):5049-59. doi: 10.1158/1078-0432.CCR-09-0632. Epub 2009 Aug 11.

25.

Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasible.

Dang C, D'Andrea G, Lake D, Sugarman S, Fornier M, Moynahan ME, Gilewski T, Hurria A, Mills N, Troso-Sandoval T, George R, Robson M, Dickler M, Smith K, Panageas KS, Norton L, Hudis CA.

Clin Breast Cancer. 2008 Oct;8(5):418-24. doi: 10.3816/CBC.2008.n.050.

PMID:
18952555
26.

The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer.

Dang C, Fornier M, Sugarman S, Troso-Sandoval T, Lake D, D'Andrea G, Seidman A, Sklarin N, Dickler M, Currie V, Gilewski T, Moynahan ME, Drullinsky P, Robson M, Wasserheit-Leiblich C, Mills N, Steingart R, Panageas K, Norton L, Hudis C.

J Clin Oncol. 2008 Mar 10;26(8):1216-22. doi: 10.1200/JCO.2007.12.0733.

PMID:
18323546
27.

A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer.

Modi S, Seidman AD, Dickler M, Moasser M, D'Andrea G, Moynahan ME, Menell J, Panageas KS, Tan LK, Norton L, Hudis CA.

Breast Cancer Res Treat. 2005 Mar;90(2):157-63.

PMID:
15803362
28.

Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer.

Dang CT, D'Andrea GM, Moynahan ME, Dickler MN, Seidman AD, Fornier M, Robson ME, Theodoulou M, Lake D, Currie VE, Hurria A, Panageas KS, Norton L, Hudis CA.

Clin Cancer Res. 2004 Sep 1;10(17):5754-61.

29.

Involvement of mammalian Mus81 in genome integrity and tumor suppression.

McPherson JP, Lemmers B, Chahwan R, Pamidi A, Migon E, Matysiak-Zablocki E, Moynahan ME, Essers J, Hanada K, Poonepalli A, Sanchez-Sweatman O, Khokha R, Kanaar R, Jasin M, Hande MP, Hakem R.

Science. 2004 Jun 18;304(5678):1822-6.

30.

Eme1 is involved in DNA damage processing and maintenance of genomic stability in mammalian cells.

Abraham J, Lemmers B, Hande MP, Moynahan ME, Chahwan C, Ciccia A, Essers J, Hanada K, Chahwan R, Khaw AK, McPherson P, Shehabeldin A, Laister R, Arrowsmith C, Kanaar R, West SC, Jasin M, Hakem R.

EMBO J. 2003 Nov 17;22(22):6137-47.

31.

BARD1 participates with BRCA1 in homology-directed repair of chromosome breaks.

Westermark UK, Reyngold M, Olshen AB, Baer R, Jasin M, Moynahan ME.

Mol Cell Biol. 2003 Nov;23(21):7926-36.

32.

The cancer connection: BRCA1 and BRCA2 tumor suppression in mice and humans.

Moynahan ME.

Oncogene. 2002 Dec 16;21(58):8994-9007. Review.

33.

ATP hydrolysis by mammalian RAD51 has a key role during homology-directed DNA repair.

Stark JM, Hu P, Pierce AJ, Moynahan ME, Ellis N, Jasin M.

J Biol Chem. 2002 Jun 7;277(23):20185-94. Epub 2002 Mar 28.

34.

Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma.

Fornier MN, Seidman AD, Theodoulou M, Moynahan ME, Currie V, Moasser M, Sklarin N, Gilewski T, D'Andrea G, Salvaggio R, Panageas KS, Norton L, Hudis C.

Clin Cancer Res. 2001 Dec;7(12):3934-41.

35.

Double-strand breaks and tumorigenesis.

Pierce AJ, Stark JM, Araujo FD, Moynahan ME, Berwick M, Jasin M.

Trends Cell Biol. 2001 Nov;11(11):S52-9. Review.

PMID:
11684443
36.
37.

Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.

Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A, Panageas KS, Arroyo C, Valero V, Currie V, Gilewski T, Theodoulou M, Moynahan ME, Moasser M, Sklarin N, Dickler M, D'Andrea G, Cristofanilli M, Rivera E, Hortobagyi GN, Norton L, Hudis CA.

J Clin Oncol. 2001 May 15;19(10):2587-95.

PMID:
11352950
38.

BRCA2 is required for homology-directed repair of chromosomal breaks.

Moynahan ME, Pierce AJ, Jasin M.

Mol Cell. 2001 Feb;7(2):263-72.

39.

Homologous recombination between heterologs during repair of a double-strand break. Suppression of translocations in normal cells.

Richardson C, Moynahan ME, Jasin M.

Ann N Y Acad Sci. 1999;886:183-6. Review. No abstract available.

PMID:
10667215
40.

Brca1 controls homology-directed DNA repair.

Moynahan ME, Chiu JW, Koller BH, Jasin M.

Mol Cell. 1999 Oct;4(4):511-8.

41.

Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer.

D'Andrea G, Fennelly D, Norton L, Baselga J, Gilewski T, Hudis C, Moynahan ME, Raptis G, Sklarin N, Surbone A, Theodoulou M, Templeton MA, Yao TJ, Seidman AD.

Clin Cancer Res. 1999 Feb;5(2):275-9.

42.
43.

Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.

Seidman AD, Hudis CA, Albanell J, Tong W, Tepler I, Currie V, Moynahan ME, Theodoulou M, Gollub M, Baselga J, Norton L.

J Clin Oncol. 1998 Oct;16(10):3353-61. Review. Erratum in: J Clin Oncol. 2006 May 10;24(14):2220. Albanel, J [corrected to Albanell, J ].

PMID:
9779712
44.

Dose-dense therapy with paclitaxel via weekly 1-hour infusion: preliminary experience in the treatment of metastatic breast cancer.

Seidman AD, Hudis CA, McCaffrey J, Tong W, Currie V, Moynahan ME, Theodoulou M, Tepler I, Gollub M, Norton L.

Semin Oncol. 1997 Oct;24(5 Suppl 17):S17-72-S17-76.

PMID:
9374099
45.

Loss of heterozygosity induced by a chromosomal double-strand break.

Moynahan ME, Jasin M.

Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):8988-93.

46.

Targeted transgenesis.

Jasin M, Moynahan ME, Richardson C.

Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):8804-8. No abstract available.

47.

A model for testing recombinogenic sequences in the mouse germline.

Moynahan ME, Akgün E, Jasin M.

Hum Mol Genet. 1996 Jul;5(7):875-86.

PMID:
8817322
48.

Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer.

Seidman AD, Hochhauser D, Gollub M, Edelman B, Yao TJ, Hudis CA, Francis P, Fennelly D, Gilewski TA, Moynahan ME, Currie V, Baselga J, Tong W, O'Donaghue M, Salvaggio R, Auguste L, Spriggs D, Norton L.

J Clin Oncol. 1996 Jun;14(6):1877-84.

PMID:
8656256
49.

Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.

Hudis CA, Seidman AD, Baselga J, Raptis G, Lebwohl D, Gilewski T, Currie V, Moynahan ME, Sklarin N, Fennelly D, et al.

Semin Oncol. 1995 Dec;22(6 Suppl 15):18-23.

PMID:
8643965
50.

Binding, internalization, and degradation of [125I]insulin by cultured bovine aortic endothelial cells: effects of serotonin.

Carson MP, Peterson SW, Moynahan ME, Shepro D.

In Vitro. 1983 Nov;19(11):833-40.

PMID:
6360849

Supplemental Content

Loading ...
Support Center